Rituximab in relapsed aggressive lymphoma: play it again, Sam?
Dreyling
Martin
M
Department of Internal Medicine III, Klinikum der Universität München, Campus Grosshadern, Germany. Martin.Dreyling@med.uni-muenchen.de
Schmidt
Christian
C
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D008495:Medical Oncology / Q000379:methods*; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone